On the other hand, SIRT6-mediatedsuppression of ERK2 and p90RSK signaling increases resistanceto DNA-damaging therapeutics.76 Upregulationof SIRT6 has also been observed in other blood cancers, includingacute myeloid leukemia,77 chronic lymphocyticleukemia,78 and diffuse large B-cell lymphoma(DLBCL).79 In DLBCL cells, knockdown ofSIRT6 leads to higher sensitivity to chemotherapy, altered cell proliferation,augmented rates of apoptosis, and cell cycle arrest. This evidence concerns the gene RPS6KA1 and diffuse large B-cell lymphoma.